The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Epysqli eculizumab BiosimilarAdditional monitoring | Samsung Bioepis NL B.V. | Hemoglobinuria, Paroxysmal | 🇪🇺 EU 2023-05-26 | Order → |
| Omvoh mirikizumab Additional monitoring | Eli Lilly Nederland B.V. | Colitis, Ulcerative | 🇪🇺 EU 2023-05-26 | Order → |
| Pedmarqsi sodium thiosulfate | Norgine B.V. | Ear Diseases; Ototoxicity | 🇪🇺 EU 2023-05-26 | Order → |
| Qaialdo spironolactone | Lipomed GmbH | Edema; Heart Failure; Liver Cirrhosis; Ascites; Nephrotic Syndrome; Hyperaldosteronism; Essential Hypertension | 🇪🇺 EU 2023-05-26 | Order → |
| Sugammadex Adroiq sugammadex | Extrovis EU Ltd | Neuromuscular Blockade | 🇪🇺 EU 2023-05-26 | Order → |
| Hyftor sirolimus Orphan | Plusultra pharma GmbH | Angiofibroma; Tuberous Sclerosis | 🇪🇺 EU 2023-05-15 | Order → |
| Elfabrio pegunigalsidase alfa | Chiesi Farmaceutici S.p.A | Fabry Disease | 🇪🇺 EU 2023-05-04 | Order → |
| Tibsovo ivosidenib OrphanAdditional monitoring | Les Laboratoires Servier | Leukemia, Myeloid, Acute; Cholangiocarcinoma | 🇪🇺 EU 2023-05-04 | Order → |
| Vafseo vadadustat Additional monitoring | Medice Arzneimittel Pütter GmbH & Co. KG | Renal Insufficiency, Chronic; Anemia | 🇪🇺 EU 2023-04-24 | Order → |
| Akeega niraparib;abiraterone acetate | Prostatic Neoplasms, Castration-Resistant | 🇪🇺 EU 2023-04-19 | Order → | |
| Bekemv eculizumab Biosimilar | Amgen Europe B.V. | Hemoglobinuria, Paroxysmal | 🇪🇺 EU 2023-04-19 | Order → |
| Opzelura ruxolitinib | Incyte Biosciences Distribution B.V. | Vitiligo; Dermatitis, Atopic | 🇪🇺 EU 2023-04-19 | Order → |
| Sitagliptin / Metformin hydrochloride Sun sitagliptin;metformin hydrochloride Generic | Sun Pharmaceutical Industries Europe B.V. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2023-03-31 | Order → |
| Bimervax COVID-19 Vaccine (recombinant, adjuvanted) Additional monitoring | Hipra Human Health S.L. | COVID-19 virus infection | 🇪🇺 EU 2023-03-30 | Order → |
| Dapagliflozin Viatris dapagliflozin Generic | Viatris Limited | Diabetes Mellitus, Type 2; Heart Failure, Systolic; Heart Failure; Renal Insufficiency, Chronic | 🇪🇺 EU 2023-03-24 | Order → |
| Sotyktu deucravacitinib Additional monitoring | Bristol-Myers Squibb Pharma EEIG | Psoriasis | 🇪🇺 EU 2023-03-24 | Order → |
| Pombiliti cipaglucosidase alfa Additional monitoring | Amicus Therapeutics Europe Limited | Glycogen Storage Disease Type II | 🇪🇺 EU 2023-03-20 | Order → |
| Hemgenix etranacogene dezaparvovec OrphanPRIMEATMP | CSL Behring GmbH | Hemophilia B | 🇪🇺 EU 2023-02-20 | Order → |
| Imjudo tremelimumab Additional monitoring | AstraZeneca AB | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2023-02-20 | Order → |
| Tremelimumab AstraZeneca tremelimumab Additional monitoring | AstraZeneca AB | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2023-02-20 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.